ABSTRACT Mycoplasma gallisepticum (M. gallisepticum) remains one of the most important diseases in poultry production. Controlling the impact of the disease is done by eradication of positive breeder flocks or by vaccination and medication. A widely used molecule in medication programs is tiamulin, a pleuromutilin antibiotic. Since recent data on the in vivo efficacy of this molecule are scarce, 2 challenge studies were conducted using a recently isolated M. gallisepticum strain belonging to the wildtype population with regard to its tiamulin and tetracycline minimum inhibitory concentration (MIC). In the first challenge study, the dose rate of tiamulin was tested. For this, broilers were infected with M. gallisepticum and treated with 10 mg or 25 mg tiamulin hydrogen fumarate (hf)/kg body weight (BW) for 5 successive days. In a second challenge study, the dose rate of tiamulin combined with chlortetracycline was tested. For this, broilers were infected with M. gallisepticum and treated with 6.25 mg tiamulin hf/18.75 mg chlortetracycline hydrochloride (hcl)/kg BW or 12.5 mg tiamulin hf/37.5 mg chlortetracycline hcl/kg BW for 5 successive days. Clinical scoring of respiratory signs, macroscopic scoring of respiratory tract lesions, M. gallisepticum isolation from the respiratory organs, weight gain, and mortality were the monitored efficacy parameters. The first study demonstrated that a 5-day 10 mg/kg BW tiamulin hf treatment provided significant protection against the M. gallisepticum infection. However, since the 5-day 25 mg/kg BW group was significantly better than the 10 mg/kg BW for reducing the post-treatment clinical signs and the M. gallisepticum numbers in the respiratory organs, the 25 mg/kg BW treatment is recommended for clinical M. gallisepticum infections. In the second study, the combined 12.5 mg tiamulin hf/37.5 mg chlortetracycline hcl/kg BW resulted in a significant reduction of the severity of clinical respiratory disease post treatment and a significant reduction of the M. gallisepticum numbers in the respiratory tract.
INTRODUCTION
Mycoplasma gallisepticum (M. gallisepticum) infection, commonly referred to as "chronic respiratory disease," is characterized by nasal discharge, tracheal rales, coughing, and dyspnea (Levisohn and Kleven, 2000) . Because of growth retardation, increased feed conversion rates, increased mortality rates, increased condemnation rates at processing, and egg production declines in laying flocks, as well as increased medication costs, it is regarded as one of the most costly infectious diseases in modern intensive poultry production (Raviv and Hey, 2013) . Controlling the impact of the disease on a global level is done by eradication of positive breeder flocks or by vaccination and medication (Kleven, 2008) . One of the most widely used molecules in medication programs is tiamulin, a pleuromutilin antibiotic (Islam et al., 2009 ). However, there are only few data on the in vivo efficacy of this molecule (Baughn et al., 1978; Jordan et al., 1989; Jordan et al., 1998) . Moreover, important differences in official registered dosage can be found across countries and even more important are the inconsistencies in actual given dosages that can be found all over the world. These differences in actually used dosages cannot solely be attributed to regional differences in susceptibility of the causative organism to tiamulin. To establish an efficient posology for this important disease, a dose titration study was conducted. Based on the pharmacokinetic/pharmacodynamic features of this antimicrobial product, the efficacy of a 3367 5-day 25 mg/kg body weight (BW) and 10 mg/kg BW tiamulin treatment was tested.
It has been demonstrated that chlortetracycline, when simultaneously administered with tiamulin, shows a synergistic antimicrobial effect (Burch and Stipkovits, 1994) . This might imply that a combination therapy with these 2 antimicrobial products might allow a reduction of the tiamulin dosage necessary for M. gallisepticum disease control, reducing the potential toxic drug effects of tiamulin. Well-known are, for instance, the clinically important, dose dependent lethal interactions between the ionophore anticoccidials and tiamulin (Islam et al., 2009 ). To test this hypothesis, a second dose titration study was conducted to test the efficacy of a 5-day 12.5/37.5 mg/kg BW and 5-day 6.25/18.75 mg/kg BW tiamulin/chlortetracycline treatment.
MATERIALS AND METHODS

Chickens
Unvaccinated ROSS broiler chickens from a local company (Vervaeke, Tielt) were used in the study. The chickens were raised according to routine procedures until M. gallisepticum challenge infection at 10 d of age. At 5 d of age, each bird was identified by means of a uniquely numbered wing tag.
The birds were housed on fresh litter in separate isolation rooms with HEPA-filtered air, had free access to food and water, and received 20 h of light per day. Tracheal swabs taken from all chickens at 9 d of age were negative for M. gallisepticum after qPCR analysis.
Mycoplasma Strain and Culture Conditions
For the Mycoplasma challenge, a recent M. gallisepticum field isolate, strain 236 MIC value of <0.015 μg/mL for tiamulin, one μg/mL for doxycycline, and 2 μg/mL for oxytetracycline was used. The strain was stored at −70
• C in Mycoplasma broth (Difco TM PPLO broth (BD, Franklin Lakes, NJ, USA) supplemented with 1% D(+) Glucose monohydrate (Merck, Overijse, Belgium), 0,5% Phenol red (sodium salt) indicator (Merck, Overijse, Belgium), 10% Select Yeast Extract (Invitrogen, Carlsbad, CA), 25% Inactivated Horse Serum (Invitrogen, Carlsbad, CA), and amoxicillin (one mg/mL) (Bradbury, 1998) . One mL of the stored broth (−70
• C) was added to 20 mL Mycoplasma broth, which was then incubated for 2 d at 37
• C until change of color from red to yellow was observed (Mekkes and Feberwee, 2005) . A control of the bacterial concentration of the inoculum was done by inoculating 10-fold dilutions in Mycoplasma broth after which the number of color changing units (ccu) was determined.
Experimental Design
Two experimental trials were performed. For each trial 45 one-day-old ROSS broiler chickens were randomly divided into 3 groups of 15 animals each. At 10 d of age, all chickens were inoculated intratracheally with 100 μl Mycoplasma broth containing 7 log 10 ccu of M. gallisepticum.
After infection, all birds were examined clinically and scored for respiratory symptoms on a daily basis until they were sacrificed.
Tracheal samples were taken one d and 6 d post M. gallisepticum inoculation (dpi) using cotton-tipped aluminum shafted swabs (Copan Diagnostics Inc., Murrietta, CA, USA) and tested for the presence of M. gallisepticum DNA by quantitative polymerase chain reaction (qPCR). The birds were weighed one, 6, and 11 dpi. Six dpi, 5 birds/group with the highest wing number were sacrificed. Eleven dpi, the remaining birds were sacrificed. Euthanasia was performed by intravenous injection with an overdose (100 mg/kg) of sodium pentobarbital 20% (Kela, Hoogstraten, Belgium). The birds were weighed, necropsied, and examined for gross lesions. In addition, swabs of the trachea, the lungs, and air sacs were collected for M. gallisepticum examination using qPCR.
This experiments were approved by the Ethical Committee of the Faculty of Veterinary Medicine, Ghent University.
Antimicrobial Treatments
In trial 1, 2 chicken groups received tiamulin treatment by medicating the drinking water for 5 consecutive days. Group T 10 received 10 mg tiamulin hydrogen fumerate (Vetmulin R 450 mg/g Granules)/kg BW per d, and group T 25 received 25 mg tiamulin hydrogen fumerate/kg BW per day. Control group C1 remained untreated.
In trial 2, 2 groups received combined tiamulinchloretracycline treatment through feed medication for 5 consecutive days. Chickens in group T 12.5 received 12.5 mg tiamulin hydrogen fumerate/37.5 mg chlortetracycline (Rododet R )/kg BW per day. Chickens in group T 6.25 received 6.25 mg tiamulin hydrogen fumerate/18.75 mg chlortetracycline/kg BW per day. Control group C2 remained untreated.
In both trials, antimicrobial treatment started one d after M. gallisepticum inoculation. In each group, water uptake (trial 1) or feed intake (trial 2) was recorded daily starting one d before treatment and continuing to the end of the treatment period. In addition, the body weight of each bird was determined daily during treatment. The arithmetic mean body weight per group was calculated. On the basis of these data, the antimicrobial concentrations to be administered in the water and the actual received dosages were calculated.
Clinical Score
The clinical score given to a chicken is the sum of the scores for each sign of respiratory distress. A score of 1 was given for a positive trachea reflex, presence of 
qPCR Analysis of Tracheal, Lung, and Air Sac Swabs
All swabs were suspended in one mL PBS. After 20 min shaking, the swabs were removed and the suspension was prepared for DNA isolation. Quantification of M. gallisepticum by qPCR was performed as described by Mekkes & Feberwee (2005) , after which the number of genomic equivalents (GE)/mL was calculated.
Statistical Analyses
M. gallisepticum GE from tracheal swabs and clinical scores were analyzed for all birds between zero and 6 dpi and subsequently from the birds that were not euthanized between zero and 11 dpi. Weight gains were analyzed for animals that were not euthanized at 6 dpi between zero and 11 dpi. The area under the curve (AUC) of the clinical scores and tracheal swabbing was analyzed using a fixed-effects model with the treatment group as fixed effect.
Weight gain was compared at the end of the trial using a fixed-effects model.
M. gallisepticum GE from the trachea, lungs, and air sacs of the animals, euthanized at 6 dpi, were compared among the treatment groups with the Kruskall-Wallis test.
All tests were performed at a global 5% significance level and the pairwise comparisons were tested at a significance level adjusted using Bonferroni's multiple comparisons technique (Agresti, 2002) .
RESULTS
Mortality
In trial 1, 2 chickens died before the planned necropsy date. One chicken from C1 died 4 dpi and one bird of group T25 died 8 dpi, 2 d after final treatment. Both birds died after relatively mild respiratory distress. The first chicken showed lesions of fibrinous tracheitis, airsaculitis, pneumonia, perihepatitis, and pericarditis. The second suffered from trachea and lung congestion and a swollen liver. Q-PCR analysis showed high GE values in the respiratory organs. Swabs from the affected organs also were collected and tested for E. coli. All sampled organs were positive for E. coli after inoculation on McConkey agar plates. These results are evidence that the birds died due to the Mycoplasma infection, complicated by secondary E. coli infection resulting in polyserositis and sepsis.
In trial 2, 2 chickens died before the planned necropsy in group C2 as well as in group T6.25. All 4 birds died after severe signs of respiratory distress and necropsy revealed the presence of respiratory lesions. Q-PCR analysis of the swabbed respiratory organs showed high GE values in the respiratory organs (trachea, air sacs, and lungs). Swabs from the lung, trachea, air sac, liver and pericard also were collected and inoculated on McConkey agar plates. They all tested negative for E. coli. These results are evidence that the birds died due to the Mycoplasma infection. In group T12.5, spontaneous deaths did not occur.
Clinical Signs
Mean clinical scoring results are shown in Figure 1 . Signs of respiratory disease were seen in all groups starting from one dpi.
Trial 1: In group C1, mean clinical scores rapidly increased after M. gallisepticum infection. All birds showed signs of respiratory distress and high mean clinical scores (3.78) were observed until the end of the trial. In group T10, signs of respiratory disease were less pronounced (mean clinical scores ≤1.90). In group T25, only mild respiratory disease signs were noticed (mean clinical scores ≤1.00)
Using the average of the clinical scores from zero to 6 dpi and from zero to 11 dpi, there was a statistically significant difference among the 3 experimental groups (P < 0.001). From the pairwise comparisons, group T25 and group T10 differed significantly from the control group for both analyzed time spans (P ≤ 0.007). From zero to 6 dpi, a significant difference between group T25 and group T10 was not observed (P = 0.825). From zero to 11 dpi, group T25 differed significantly from group T10 (P = 0.031).
Trial 2: In group C2, mean clinical scores rapidly increased after M. gallisepticum infection. All birds showed signs of respiratory distress, and high mean clinical scores (3.38) were observed until the end of the trial. In the tiamulin treated groups, signs of respiratory disease were less pronounced (in group T6.25: mean scores ≤2.63; in group T12.5: mean scores ≤1.30).
Using the average of the clinical scores, there was a statistically significant difference among the 3 experimental groups (P < 0.001). From the pairwise comparisons, both group T12.5 and T6.25 differed significantly from group C2 (P < 0.001). A significant difference be- tween the 2 tiamulin groups was not observed (P > 0.05). These statistical results were the same for both analyzed time spans (zero to 6 dpi and zero to 11 dpi).
Macroscopic Findings
The incidence of the macroscopic lesions observed during necropsy are illustrated in Table 2 .
Trial 1: At necropsy 6 dpi, highest mean respiratory lesion incidence was seen in group C1 (67%). In the tiamulin treated groups, mean respiratory lesion incidences were lower: 40 and 47% in group T10 and group T25, respectively. Among experimental groups, statistical significant differences were not observed (P > 0.05).
For the birds of each experimental group, sacrificed at 11 dpi, highest respiratory lesion incidence was seen in the C1 (96%). In the tiamulin treated groups, lesion incidences were 67 and 37% in group T10 and group T25, respectively. Statistically significant differences between group T25 and C1 were observed for tracheitis (P < 0.02) and pneumonia (P < 0.015).
Trial 2: At necropsy 6 dpi, highest respiratory lesion incidences were seen in group C2 and group T6.25 (67%). In group T12.5, lesion incidence was 33%. Among experimental groups, significant differences were not observed (P > 0.05).
At necropsy 11 dpi, highest respiratory lesion incidence was seen in group C2 (83%), followed by group T6.25 (75%) and group T 12.5 (60%). Among experimental groups, statistically significant differences were not observed (P > 0.05).
Presence of M. Gallisepticum in Tracheal Mucus
The results of the qPCR analysis of the tracheal swabs (mean GE values) are shown in Figure 2 . One dpi, high tracheal GE values of M. gallisepticum were observed in every experimental group (mean tracheal GE values >5 log 10 GE/ml), which evidences that the experimental infection was successful.
Trial 1: at 6 dpi (i.e., one d after the final treatment d), M. gallisepticum was detected in the trachea from every bird belonging to group C1 and group T10. An overall mean increase of GE values was observed in these groups with 7.03 log 10 GE/mL in group C1 and 6.79 log 10 GE/mL in group T10. These GE levels were maintained until the end of the trial.
In group T25, at 6 dpi, 6 birds proved negative for M. gallisepticum in the trachea and an overall mean decrease of 3 log 10 reduction of GE/ml was obtained compared to the pretreatment tracheal sample. This implies a 4 log 10 reduction compared to group C1. Eleven dpi, M. gallisepticum GE values raised to 5 log 10 GE/mL, which is a 2 log 10 reduction compared to the GE level in C1.
Using the average count in the fixed-effects model, there was a statistically significant difference among the 3 experimental groups (P < 0.001). For the significant pairwise comparisons, T25 differed significantly from T10 (P ≤ 0.007) and C1 (P ≤ 0.001) for both analyzed time spans.
Trial 2: Six dpi, M. gallisepticum was still present in every trachea from birds belonging to C2. Compared to the previous tracheal sampling (one dpi), an average increase of 1.7 log 10 GE values was detected. Six dpi, M. gallisepticum could not be detected in the trachea of one bird in group T6.25. A slight increase in mean GE values (0.9 log 10 GE) was observed compared to the pretreatment tracheal sample (one dpi). In group T12.5, M. gallisepticum was detected in every trachea. A small decrease (0.32 log 10 GE) in mean GE values could be observed compared to the pretreatment sample (one dpi). At the end of the experiment, 11 dpi, M. gallisepticum GE values in the tiamulin treated groups raised to the same level as the GE in control group C2.
Using the average count in the fixed-effects model from one to 6 dpi, there was a statistically significant difference among the 3 experimental groups (P = 0.019). For the significant pairwise comparisons, T12.5 differed significantly from group C2 (P = 0.024).
Presence of M. Gallisepticum in Organ Swabs
The results of the qPCR analysis of the respiratory organs (mean GE values) of the birds necropsied at 6 dpi and 11 dpi are shown in Table 3 .
Trial 1: At 6 dpi, significant differences among experimental groups were observed for M. gallisepticum GE detected in the trachea, air sacs, and lungs. The following pairwise significant comparisons were noted for the M. gallisepticum GE in the trachea: group T25 differed significantly from group C1 (P = 0.016) and group T10 (P = 0.016). For the M. gallisepticum GE in the air sacs, group T25 differed significantly from group C1 (P = 0.016). For the M. gallisepticum GE in the lungs, group T25 differed significantly from T10 mg/kg treatment (P = 0.008).
At 11 dpi, statistically significant differences among the experimental groups were observed for M. gallisepticum GE detected in the trachea, air sacs, and lungs. For all organs, T25 differed significantly from group C1 (trachea P <0.001; air sacs: P = 0.004; lungs: P = 0.004). In addition, for the GE in the trachea, group T25 differed significantly from group T10 (P = 0.001).
Trial 2: At 6 dpi, significant differences among experimental groups were observed for M. gallisepticum GE detected in the air sacs and lungs. For the M. gallisepticum GE in the air sacs, group T12.5 differed significantly from group C2 (P = 0.016). For the M. gallisepticum GE in the lungs, group T12.5 differed significantly from group T6.25 (P = 0.032). Table 3 . Genomic equivalents (GE) of M. gallisepticum in organs (mean value [standard error]) of chickens inoculated with M. gallisepticum and treated with different tiamulin dosage schemes for 5 successive days. Trial 1: 25 mg/kg tiamulin (T 25 ), 10 mg/kg tiamulin (T 10 ), or no treatment (C1). Trial 2: 12.5 mg/kg tiamulin combined with 37.5 mg/kg chlortetracycline (T 12.5 ), 6.25 mg/kg tiamulin combined with 18.75 mg/kg chlortetracycline (T 6.25 ), or no treatment (C2).
GE of M. gallisepticum in organs (log 10 GE/mL suspension) 6 dpi * 11 dpi At 11 dpi, group T12.5 showed the lowest M. gallisepticum titers in the lower respiratory tract (air sacs, lungs). Highest lower respiratory tract titeers were observed in group T6.25. Statistically significant differences among the experimental groups were not observed (P > 0.05).
Weight
The mean weight gains of the birds in the different groups are presented in Figure 3 .
Trial 1: In the period after M. gallisepticum infection (one to 11 dpi), an overall mean weight gain of 387 g was obtained in the birds of group C1. In the same period, birds in group T10 obtained an overall mean weight gain of 422 g, and birds in group T25 obtained an overall mean weight gain of 532 g.
A statistically significant difference was observed between group T25 and group C1 (P = 0.042).
Trial 2: Between one and 11 dpi, an overall mean weight gain of 445 g was obtained in the birds of group C2. In the same period, in the birds of group T6.25 and group T12.5 an overall mean weight gain of 543 g and 532 g, respectively, was obtained. Statistically significant differences were not noticed among the experimental groups (P > 0.05).
DISCUSSION
In the first trial, the efficacy of a 5-day 10 mg/kg and a 25 mg/kg BW tiamulin treatment against an experimental M. gallisepticum infection in broilers was tested. Both dosage schemes were able to reduce the severity of clinical respiratory disease, reducing macroscopic lesions in the respiratory organs and obtaining higher weight gains compared to the untreated control group. Compared to the 10 mg/kg BW tiamulin treatment, the 25 mg/kg BW tiamulin treatment also significantly reduced the M. gallisepticum numbers in the respiratory tract. For the post-treatment period and until the end of the monitoring, the 25 mg/kg BW tiamulin treatment resulted in significantly lower clinical scores than the 10 mg/kg BW tiamulin treatment. This was not the case during treatment days. For the other parameters, significant differences in efficacy between the 2 dosage schemes were not observed. These results assume that for clinical M. gallisepticum infections, a 25 mg/kg BW tiamulin treatment is recommended. The success of tiamulin against Mycoplasma induced respiratory disease is supported by its pharmacokinetic characteristics. After a single oral dose of 25 mg/kg BW, tiamulin rapidly reaches peak serum concentration of 1.7 μg/mL (Laber and Schütze, 1977) . Tiamulin is also well distributed to the respiratory tract reaching lung concentrations 30 times higher than the serum concentration (Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten, 2016, Vetmulin R 450mg/g package leaflet), which should be bacteriostatic for the Mycoplasma strain (MIC value of <0.015 μg/mL) used in the current trial (Ziv, 1980) .
The efficacy of the 25 mg/kg BW tiamulin treatment concurs with previous observations of Bhaugn et al. (1978) and Laber and Schütze (1975) . They found that tiamulin supplemented at 0.006% (Bhaugn et al., 1978) and 0.007% (Laber and Schütze, 1975) in the drinking water was able to eradicate the Mycoplasma infection in 50% of the experimentally infected broilers. These dosages comply with the amount of drugs supplemented in the drinking water in the 25 mg/kg BW tiamulin treatment (range 65 mg/L to 75 mg/L).
Tiamulin binds at the 50S ribosomal subunit with rRNA in which it prevents the correct positioning of tRNA for peptide transferase and subsequent bacterial protein production (Poulsen et al., 2001) . Like tiamulin, chlortetracycline is a protein synthesis inhibitor. Its site of action is the 30S ribosomal subunit, thereby preventing the mRNA-ribosome complex to bind the transfer-RNA during translation. This prevents the addition of amino acids to the elongating peptide chains (Giguère, 2007) . The combination of these 2 modes of actions may explain the synergistic antimicrobial effect that is shown when chlortetracycline is simultaneously administered with tiamulin (Burch and Stipkovits, 1994) . This synergistic effect can be used as a method of reducing dosage of a potential toxic drug while achieving the same therapeutic end. For instance in chickens, lethal interactions between tiamulin and the ionophore anticoccidials are well-known. This incompatibility is dose dependent, but (cardio)myopathies could be revealed already after administration of normal use levels of maduramicin, lasalocid, monensin, narasin, or salinomycin together with 20 mg/kg BW tiamulin (Madej et al., 1993) . To investigate if a combination therapy allows a reduction of the tiamulin dosage necessary for M. gallisepticum disease control, the efficacy of a 5-day 12.5/37.5 mg/kg and 6.25/18.75 mg/kg BW tiamulin/chlortetracycline treatment against experimental M. gallisepticum infection was examined. Again, both treatments reduced the severity of clinical respiratory disease, reduced macroscopic lesions in the respiratory organs, and resulted in higher weight gains compared to the untreated control group. In addition, the 5-day 12.5/37.5 mg/kg BW tiamulin/chlortetracycline resulted in significantly better reduction of the M. gallisepticum numbers in the respiratory tract. These results indicate that the use of the 5-day 12.5/37.5 mg/kg BW tiamulin/chlortetracycline treatment is successful in controlling M. gallisepticum infections, and combining tiamulin with chlortetracycline allows decreasing the dosage of tiamulin.
In both trials, complete elimination of M. gallisepticum from all birds could not be achieved. Therefore, treatment should be regarded as a method for shortterm amelioration of disease and economic effects rather than a long-term solution, since elimination of M. gallisepticum from all birds in an infected flock by antimicriobial therapy is unrealistic (Levisohn and Kleven, 2000; Reinhardt et al., 2005) . Also, to support the results of these trials, additional studies, such as dose conformation studies and field trials, should be performed.
In conclusion, in the first dose titration study, it was demonstrated that for a M. gallisepticum strain belonging to the wildtype population with regard to its tiamulin MIC, a 5-day 10 mg/kg BW tiamulin treatment was able to significantly reduce the course of respiratory disease derived from the M. gallisepticum infection compared to the untreated control group. However, the 25 mg/kg BW tiamulin treatment significantly reduced production losses, lesion scores, and M. gallisepticum numbers in the respiratory organs as compared to the untreated control group. Therefore, the 25 mg/kg BW tiamulin treatment is recommended for clinical M. gallisepticum infections. In the second study, the combined 12.5 mg tiamulin/37.5 mg chlortetracycline/kg BW resulted in a significant reduction of the severity of clinical respiratory disease during and post treatment and a significant reduction of the M. gallisepticum numbers in the respiratory tract compared to the untreated control group.
